In Vitro Comparative Study of Solid Lipid and PLGA Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin.
PLGA nanoparticles
blood-brain barrier permeability
chitosan-coating
insulin
mucoadhesion
nasal mucosa permeability
nose-to-brain delivery
solid lipid nanoparticles
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Dec 2021
09 Dec 2021
Historique:
received:
04
11
2021
revised:
03
12
2021
accepted:
06
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
2
2
2022
Statut:
epublish
Résumé
The brain insulin metabolism alteration has been addressed as a pathophysiological factor underlying Alzheimer's disease (AD). Insulin can be beneficial in AD, but its macro-polypeptide nature negatively influences the chances of reaching the brain. The intranasal (IN) administration of therapeutics in AD suggests improved brain-targeting. Solid lipid nanoparticles (SLNs) and poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are promising carriers to deliver the IN-administered insulin to the brain due to the enhancement of the drug permeability, which can even be improved by chitosan-coating. In the present study, uncoated and chitosan-coated insulin-loaded SLNs and PLGA NPs were formulated and characterized. The obtained NPs showed desirable physicochemical properties supporting IN applicability. The in vitro investigations revealed increased mucoadhesion, nasal diffusion, and drug release rate of both insulin-loaded nanocarriers over native insulin with the superiority of chitosan-coated SLNs. Cell-line studies on human nasal epithelial and brain endothelial cells proved the safety IN applicability of nanoparticles. Insulin-loaded nanoparticles showed improved insulin permeability through the nasal mucosa, which was promoted by chitosan-coating. However, native insulin exceeded the blood-brain barrier (BBB) permeation compared with nanoparticulate formulations. Encapsulating insulin into chitosan-coated NPs can be beneficial for ensuring structural stability, enhancing nasal absorption, followed by sustained drug release.
Identifiants
pubmed: 34948054
pii: ijms222413258
doi: 10.3390/ijms222413258
pmc: PMC8703723
pii:
doi:
Substances chimiques
Insulin
0
Lipid Nanoparticles
0
Liposomes
0
Polyglycolic Acid
26009-03-0
Chitosan
9012-76-4
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Arch Neurol. 2012 Jan;69(1):29-38
pubmed: 21911655
J Neurosci. 2001 Apr 15;21(8):2561-70
pubmed: 11306609
J Mater Sci Mater Med. 2007 Nov;18(11):2205-10
pubmed: 17668296
Carbohydr Polym. 2015 May 20;122:221-9
pubmed: 25817662
Int J Nanomedicine. 2007;2(4):743-9
pubmed: 18203440
Nat Neurosci. 2015 Jun;18(6):800-6
pubmed: 26007213
Drug Deliv. 2016;23(3):933-9
pubmed: 24959938
J Pharm Sci. 2016 Feb;105(2):754-765
pubmed: 26869428
J Drug Target. 2011 Jul;19(6):468-74
pubmed: 20958095
Pharmaceutics. 2018 Aug 03;10(3):
pubmed: 30081536
Drug Deliv Transl Res. 2016 Aug;6(4):365-79
pubmed: 27106502
Trends Pharmacol Sci. 2017 Jul;38(7):637-648
pubmed: 28455089
J Mater Sci Mater Med. 2012 Sep;23(9):2163-75
pubmed: 22802103
Int J Biol Macromol. 2019 May 15;129:267-280
pubmed: 30726749
FASEB J. 2005 Nov;19(13):1872-4
pubmed: 16141364
Int J Nanomedicine. 2016 Jun 10;11:2641-53
pubmed: 27358561
Int J Pharm. 2016 Feb 29;499(1-2):236-246
pubmed: 26746800
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
Curr Alzheimer Res. 2012 Jan;9(1):35-66
pubmed: 22329651
J Control Release. 2018 Jan 28;270:89-100
pubmed: 29199063
Cytotechnology. 2013 May;65(3):395-406
pubmed: 22940916
Nat Rev Neurol. 2011 Mar;7(3):137-52
pubmed: 21304480
FASEB J. 2019 Mar;33(3):4458-4472
pubmed: 30676773
Lancet Neurol. 2020 Sep;19(9):758-766
pubmed: 32730766
J Microencapsul. 2007 Nov;24(7):660-72
pubmed: 17763060
Polymers (Basel). 2020 Oct 27;12(11):
pubmed: 33121199
J Alzheimers Dis. 2017;57(4):1325-1334
pubmed: 28372335
Nanoscale. 2015 Oct 28;7(40):16631-46
pubmed: 26204104
Mol Pharm. 2013 Jan 7;10(1):289-96
pubmed: 23137377
J Clin Invest. 2012 Apr;122(4):1339-53
pubmed: 22476196
Drug Dev Ind Pharm. 1999 Apr;25(4):471-6
pubmed: 10194602
Arch Med Res. 2012 Nov;43(8):600-8
pubmed: 23159715
Colloids Surf B Biointerfaces. 2014 Oct 1;122:143-150
pubmed: 25033434
Natl Vital Stat Rep. 2018 Jul;67(6):1-77
pubmed: 30248017
Front Pharmacol. 2019 Sep 12;10:1008
pubmed: 31572186
Drug Dev Ind Pharm. 2015;41(12):2037-44
pubmed: 26006329
J Clin Invest. 2012 Apr;122(4):1316-38
pubmed: 22476197
Drug Deliv Transl Res. 2021 Jan 25;:
pubmed: 33491126
Biomed Res Int. 2015;2015:320941
pubmed: 25866775
Neuropathol Appl Neurobiol. 2004 Dec;30(6):692-5
pubmed: 15541009
Toxicol In Vitro. 2012 Apr;26(3):445-54
pubmed: 22274662
P T. 2010 Apr;35(4):208-11
pubmed: 20498822
Biophys J. 2007 Apr 1;92(7):2451-62
pubmed: 17172308
Neuroscience. 2004;127(2):481-96
pubmed: 15262337
J Alzheimers Dis. 2005 Dec;8(3):247-68
pubmed: 16340083
J Alzheimers Dis. 2015;44(3):897-906
pubmed: 25374101
Eur J Pharm Sci. 2007 Jun;31(2):73-84
pubmed: 17408932
Pharmaceutics. 2021 Apr 06;13(4):
pubmed: 33917577
J Control Release. 2018 Jan 28;270:23-36
pubmed: 29196041
Tissue Barriers. 2021 Jul 3;9(3):1904773
pubmed: 34003072
Adv Drug Deliv Rev. 2018 Jan 15;124:175-183
pubmed: 29307632
Eur J Pharm Biopharm. 2012 Oct;82(2):340-51
pubmed: 22906709
Pharmaceutics. 2019 Nov 12;11(11):
pubmed: 31726699
Pharm Res. 1999 Oct;16(10):1576-81
pubmed: 10554100
Lancet Neurol. 2004 Mar;3(3):169-78
pubmed: 14980532
ISRN Biochem. 2013 May 21;2013:238428
pubmed: 25937958
ACS Appl Mater Interfaces. 2018 Mar 21;10(11):9315-9324
pubmed: 29484890
Molecules. 2019 May 21;24(10):
pubmed: 31117310
Int J Pharm. 2021 Jul 15;604:120724
pubmed: 34023443
Pharmaceutics. 2021 May 28;13(6):
pubmed: 34071664
Sci Rep. 2019 Feb 22;9(1):2621
pubmed: 30796294
Molecules. 2018 Mar 28;23(4):
pubmed: 29597330
J Pharm Sci. 2015 Oct;104(10):3544-56
pubmed: 26147711
Int J Pharm. 2018 Jan 30;536(1):478-485
pubmed: 29203137
J Alzheimers Dis. 2008 Apr;13(3):323-31
pubmed: 18430999
Curr Drug Deliv. 2005 Apr;2(2):165-75
pubmed: 16305417
Front Mol Neurosci. 2018 May 22;11:166
pubmed: 29872378
Pharmaceutics. 2019 Feb 10;11(2):
pubmed: 30744154
J Diabetes Sci Technol. 2008 Nov;2(6):1101-13
pubmed: 19885299
Drug Deliv. 2015;22(7):903-10
pubmed: 24286183
Cold Spring Harb Perspect Med. 2012 Aug 01;2(8):
pubmed: 22908189
Int J Pharm. 2009 Jun 22;375(1-2):114-22
pubmed: 19481697
Drug Des Devel Ther. 2017 Jun 19;11:1815-1825
pubmed: 28684900
J Neuroendocrinol. 2021 Apr;33(4):e12929
pubmed: 33433042
Int J Mol Sci. 2020 Jun 04;21(11):
pubmed: 32512832
Pharmaceutics. 2019 Feb 18;11(2):
pubmed: 30781722
Curr Clin Pharmacol. 2020;15(1):20-29
pubmed: 31272358
Pharmaceutics. 2018 Mar 15;10(1):
pubmed: 29543755
Eur J Pharm Biopharm. 2018 Jun;127:250-259
pubmed: 29486302
Pharm Res. 2002 Jul;19(7):998-1008
pubmed: 12180553
Mol Pharm. 2014 May 5;11(5):1550-61
pubmed: 24717116
Pharmaceutics. 2021 May 01;13(5):
pubmed: 34062873